54 citations · 78 across the 3 of their papers we have counts for
4 papers
Endpoints for randomized controlled clinical trials for COVID-19 treatments
Lori E Dodd, Dean Follmann, Jing Wang +12
Introduction: Endpoint choice for randomized controlled trials of treatments for COVID-19 is complex. A new disease brings many uncertainties, but trials must start rapidly. COVID-…
Efficient model-based Bioequivalence Testing
Kathrin Möllenhoff, Florence Loingeville, Julie Bertrand +8
The classical approach to analyze pharmacokinetic (PK) data in bioequivalence studies aiming to compare two different formulations is to perform noncompartmental analysis (NCA) fol…
Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis
Charles Burdet, Sakina Sayah-Jeanne, Thu Thuy Nguyen +7
BackgroundLowering the gut exposure to antibiotics during treatments can prevent microbiota disruption. We evaluated the effect of an activated charcoal-based adsorbent, DAV131A, o…
Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches
Soléne Desmée, France Mentré, Christine Veyrat-Follet +1
In metastatic castration-resistant prostate cancer (mCRPC) clinical trials, the assessment of treatment efficacy essentially relies on the time-to-death and the kinetics of prostat…